ELS_D86558_PSYM

Bone_300_0217

Issue link: http://digitalreprints.elsevier.com/i/104884

Contents of this Issue

Navigation

Page 0 of 7

Volume 53 / Number 6 / November-December 2012 A Neuropsychiatric Perspective of Phenylketonuria I: Overview of Phenylketonuria and Its Volume 53 / Neuropsychiatric Sequelae Number 6 / November-December 2012 Ashley Bone, M.D., Angela K. Kuehl, Pharm.D., M.S., Andrew F. Angelino, M.D., D.F.A.P.A. A Neuropsychiatric Perspective of Phenylketonuria I: Overview of Phenylketonuria and Its This article is valid for posting until 01/22/2014. Volume 53 / Number 6 / November-December 2012 Neuropsychiatric Sequelae CPC D86558 Ashley Bone, M.D., Angela K. Kuehl, Pharm.D., M.S., Andrew F. Angelino, M.D., D.F.A.P.A. This reprint is provided by BioMarin Pharmaceutical Phenylketonuria I: A Neuropsychiatric Perspective of Inc. Overview of Phenylketonuria and Its This article is valid for posting Sequelae Neuropsychiatricuntil 01/22/2014. No responsibility is assumed by Elsevier, its licensors or associates for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein. Because of rapid advances in the Ashley Bone, M.D., Angela K. Kuehl, Pharm.D., M.S., CPC D86558 medical sciences, in particular, independent verification of diagnoses and drug dosages should be made. Andrew F. Angelino, M.D., D.F.A.P.A. This reprint is provided by BioMarin Pharmaceutical Inc. This article is valid for posting until 01/22/2014. The approved indication for KUVAN�� (sapropterin dihydrochloride) Tablets is to reduce blood phenylalanine (Phe) levels in patients with hyperphenylalaninemia (HPA) due to tetrahydrobiopterin-(BH4-) responsive No responsibility is assumed by Elsevier, its licensors or associates for any injury and/or damage to persons Phenylketonuria (PKU). KUVAN is to be used in conjunction with a Phe-restricted diet. or property as a matter of products liability, negligence or otherwise, or from any use or operation of any CPC D86558 methods, products, instructions, or ideas contained in the material herein. Because of rapid advances in the medical sciences, in particular, independent verification of diagnoses and drug dosages should be made. This reprint is provided by BioMarin Pharmaceutical Inc. The approved indication for KUVAN�� (sapropterin dihydrochloride) Tablets is to reduce blood phenylalanine No responsibility patients withby Elsevier, its licensors or associates tetrahydrobiopterin-(BH4-) responsive (Phe) levels in is assumed hyperphenylalaninemia (HPA) due to for any injury and/or damage to persons or property as a matter of (PKU). KUVAN is negligence or conjunctionor from Phe-restricted diet. of any Phenylketonuria products liability, to be used in otherwise, with a any use or operation methods, products, instructions, or ideas contained in the material herein. Because of rapid advances in the medical sciences, in particular, independent verification of diagnoses and drug dosages should be made. The approved indication for KUVAN�� (sapropterin dihydrochloride) Tablets is to reduce blood phenylalanine (Phe) levels in patients with hyperphenylalaninemia (HPA) due to tetrahydrobiopterin-(BH4-) responsive Phenylketonuria (PKU). KUVAN is to be used in conjunction with a Phe-restricted diet. Visit our web sites: www.psychosomaticsjournal.org www.apm.org Of���cial Journal of the Academy of Psychosomatic Medicine

Articles in this issue

view archives of ELS_D86558_PSYM - Bone_300_0217